Imunon, Inc. (IMNN)
IMNN moved a median of 0.00% 30 minutes after news, and -1.39% by the close. How IMNN actually reacts to news — the realized, point-in-time move the market made, measured across 320 labeled events over the last three years with zero look-ahead.
IMNN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 283 |
| 30-min | 0.00% | 48% | 318 |
| 60-min | -0.12% | 46% | 319 |
| to close | -1.39% | 33% | 315 |
| Middle 50% of IMNN reactions | -1.80% to +1.64% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 320 |
Half of all Imunon, Inc. news events land between -1.80% and +1.64% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IMNN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMNN's baseline. Nothing else.
Recent IMNN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| IMUNON to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.17% | -6.96% | |
| Form 8-K Imunon, Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.56% | |
| IMUNON Converts $1.2 Million of Debt-to-Equity | Press release | GlobeNewswire | +0.00% | -2.56% | |
| IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan | Press release | GlobeNewswire | -1.39% | -6.25% | |
| IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review | Press release | GlobeNewswire | +1.33% | +5.59% | |
| IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 | Press release | GlobeNewswire | +0.60% | -12.65% | |
| IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress | Press release | GlobeNewswire | +0.00% | -1.95% | |
| IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 | Press release | GlobeNewswire | +1.54% | +0.62% | |
| Form 10-Q Imunon, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.85% | +0.00% | |
| Form 8-K Imunon, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -2.85% | +0.00% | |
| IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.85% | +0.00% | |
| IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 | Press release | GlobeNewswire | +0.63% | +5.70% | |
| IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Press release | GlobeNewswire | -0.60% | -3.61% | |
| IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development | Press release | GlobeNewswire | +0.00% | +3.75% | |
| IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer | Press release | GlobeNewswire | -7.12% | -7.22% | |
| Form 8-K Imunon, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -5.41% | +1.62% | |
| IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification | Press release | GlobeNewswire | +0.00% | -1.66% | |
| IMUNON to Present at the Life Sciences Investor Forum on June 25th | Press release | GlobeNewswire | +0.00% | -1.66% | |
| Form S-8 Imunon, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -3.19% | |
| Form 8-K Imunon, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -5.39% | -8.82% | |
| Form 8-K Imunon, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.33% | |
| IMUNON Announces Up to $10 Million Cash Financing | Press release | GlobeNewswire | +0.00% | -2.33% | |
| Form 10-Q Imunon, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.11% | +0.00% | |
| Form 8-K Imunon, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | +0.00% | |
| IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.11% | +0.00% | |
| IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 | Press release | GlobeNewswire | +0.00% | -1.07% | |
| Form 8-K Imunon, Inc. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.45% | |
| Form ARS Imunon, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -1.07% | |
| Form DEF 14A Imunon, Inc. For: May 04 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.45% | |
| Form 10-K Imunon, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.48% | +1.38% | |
| Form 8-K Imunon, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -4.48% | +1.38% | |
| IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study | Press release | GlobeNewswire | -4.48% | +1.38% | |
| IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer | Press release | GlobeNewswire | -0.96% | +6.92% | |
| IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 | Press release | GlobeNewswire | +1.36% | +0.00% | |
| Form 8-K Imunon, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +1.36% | +0.00% | |
| Form 8-K Imunon, Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | -1.92% | |
| IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY | Press release | GlobeNewswire | +0.64% | -1.92% | |
| Form 8-K Imunon, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -1.53% | |
| Form 8-K Imunon, Inc. For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +2.52% | +9.80% | |
| IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules | Press release | GlobeNewswire | -2.14% | -0.57% | |
| IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 | Press release | GlobeNewswire | -1.30% | +18.24% | |
| Form 10-Q Imunon, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.09% | — | |
| Form 8-K Imunon, Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | — | |
| Form S-8 Imunon, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.09% | — | |
| IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.09% | — | |
| IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer | Press release | GlobeNewswire | +1.86% | -0.53% | |
| IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer | Press release | GlobeNewswire | +0.74% | -7.86% | |
| IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment | Press release | GlobeNewswire | -0.50% | +0.50% | |
| IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 | Press release | GlobeNewswire | -1.06% | -2.22% | |
| IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer | Press release | GlobeNewswire | -0.24% | -8.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMNN section they belong to.
Where else IMNN is measured.
IMNN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Imunon, Inc.'s median reaction calculated?
Every labeled IMNN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 320 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of IMNN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMNN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.